![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRRC75B |
Gene summary for LRRC75B |
![]() |
Gene information | Species | Human | Gene symbol | LRRC75B | Gene ID | 388886 |
Gene name | leucine rich repeat containing 75B | |
Gene Alias | C22orf36 | |
Cytomap | 22q11.23 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q2VPJ9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
388886 | LRRC75B | male-WTA | Human | Thyroid | PTC | 8.49e-21 | 2.00e-01 | 0.1037 |
388886 | LRRC75B | PTC01 | Human | Thyroid | PTC | 1.41e-10 | 1.66e-01 | 0.1899 |
388886 | LRRC75B | PTC04 | Human | Thyroid | PTC | 1.16e-08 | 1.03e-01 | 0.1927 |
388886 | LRRC75B | PTC05 | Human | Thyroid | PTC | 1.42e-04 | 1.93e-01 | 0.2065 |
388886 | LRRC75B | PTC06 | Human | Thyroid | PTC | 3.65e-16 | 3.75e-01 | 0.2057 |
388886 | LRRC75B | PTC07 | Human | Thyroid | PTC | 6.27e-35 | 2.02e-01 | 0.2044 |
388886 | LRRC75B | ATC12 | Human | Thyroid | ATC | 5.27e-10 | 5.35e-02 | 0.34 |
388886 | LRRC75B | ATC13 | Human | Thyroid | ATC | 1.13e-16 | 2.62e-01 | 0.34 |
388886 | LRRC75B | ATC4 | Human | Thyroid | ATC | 4.39e-04 | 5.48e-02 | 0.34 |
388886 | LRRC75B | ATC5 | Human | Thyroid | ATC | 3.49e-16 | 2.90e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Thyroid | PTC | ![]() |
Thyroid | goiters | ![]() |
Thyroid | ATC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRC75B | SNV | Missense_Mutation | rs202133451 | c.400N>T | p.Arg134Cys | p.R134C | Q2VPJ9 | protein_coding | tolerated(0.12) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LRRC75B | SNV | Missense_Mutation | c.411G>C | p.Lys137Asn | p.K137N | Q2VPJ9 | protein_coding | deleterious(0) | possibly_damaging(0.714) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
LRRC75B | SNV | Missense_Mutation | rs369950570 | c.617N>T | p.Ala206Val | p.A206V | Q2VPJ9 | protein_coding | tolerated(0.15) | benign(0.001) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LRRC75B | SNV | Missense_Mutation | novel | c.187N>A | p.Leu63Ile | p.L63I | Q2VPJ9 | protein_coding | deleterious(0.03) | probably_damaging(0.937) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
LRRC75B | SNV | Missense_Mutation | c.715N>T | p.Pro239Ser | p.P239S | Q2VPJ9 | protein_coding | tolerated(0.05) | benign(0.134) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
LRRC75B | SNV | Missense_Mutation | c.838N>A | p.Leu280Met | p.L280M | Q2VPJ9 | protein_coding | tolerated(0.06) | benign(0.052) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRRC75B | SNV | Missense_Mutation | rs577321478 | c.517C>T | p.Arg173Cys | p.R173C | Q2VPJ9 | protein_coding | tolerated(0.18) | benign(0.311) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
LRRC75B | SNV | Missense_Mutation | c.650N>A | p.Gly217Asp | p.G217D | Q2VPJ9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRRC75B | SNV | Missense_Mutation | c.650G>A | p.Gly217Asp | p.G217D | Q2VPJ9 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LRRC75B | SNV | Missense_Mutation | c.908C>A | p.Ala303Asp | p.A303D | Q2VPJ9 | protein_coding | deleterious(0.03) | possibly_damaging(0.651) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |